Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
Revance Therapeutics (NASDAQ: RVNC ) has filed a marketing application in the U.S. seeking approval of DAXI (daxibotulinumtoxinA for injection) for the treatment of moderate-to-severe glabellar (frown) lines. The agency's action date is November 25. More news on: Revance Therapeutics, In...
Ipsen ( OTCPK:IPSEY ) has suspended dosing in its Phase 3 clinical trial, PVO-1A-301 , evaluating palovarotene in patients with fibrodysplasia ossificans progressiva (FOP) as well as its Phase 2 extension studies, PVO-1A-202 and PVO-1A-204 , after a futility analysis by the Independent...
Ipsen has decided to pause dosing in the palovarotene trials Based on encouraging therapeutic activity signals observed in preliminary post-hoc analyses and recommendations from the Independent Data Monitoring Committee, Ipsen to conduct further assessment of the complete data set a...
The following slide deck was published by Ipsen S.A. in conjunction with this Read more ...
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200113005846/en/ (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Dr. Steven Hildemann as Executive Vice President...
Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191217005938/en/ Aymeric Le Chatelier, Interim CEO, Ipsen (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) today announced that David Mee...
Editor's note: Seeking Alpha is proud to welcome Michal Kalisiak as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA PREMIUM. Click here to find out more » Company Ipsen...
The FDA has instituted a partial clinical hold on four studies evaluating Ipsen's ( OTCPK:IPSEY ) palovarotene due to a potential safety signal in patients under the age of 14. Specifically, there have been reports of early growth plate closure in patients with fibrodysplasia ossificans p...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following discussions with the U.S. Food and Drug Administration (FDA), that a partial clinical hold effective immediately, for the pediatric population under the age of 14 was issued for studies conducted under IND120181...
Thinly traded nano cap Merrimack Pharmaceuticals ( MACK +6.1% ) is up on almost 30% higher volume, albeit on turnover of only 66K shares, on the heels of its announcement that it has received a $5M milestone payment from Ipsen S.A. ( OTCPK:IPSEY ) triggered by the latter's decision to ad...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...